Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI0457 plus Durvalumab in HPV+ HNSCC
NCT03162224Phase 2Completed
- Sponsor
- MedImmune
- Start
- Jun 2017
- Primary completion
- Mar 2021
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of MEDI0457 in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by MedImmune. Primary endpoints: Treatment Emergent Adverse Events, Abnormal Laboratory Parameters and 5 more. Started Jun 2017; status: completed.
02
Drugs
MEDI0457
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03162224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03162224.